From: The Brazilian Society of Rheumatology guidelines for axial spondyloarthritis – 2019
Outcome | mSASSS variation (units) | |||
---|---|---|---|---|
Follow-up time (years) | ||||
0 to 2 | 0 to 4 | |||
Drug | Δ mSASSS | 95% CI | Δ mSASSS | 95% CI |
Infliximab [171, 172] | 0.9 | 0.54–1.26 | 1.60 | 1.1–2.1 |
Etanercept [173] | 0.91 | 0.62–1.21 | ||
Adalimumab [174] | 0.9 | 0.51–1.09 | ||
Golimumab [175] | 0.9 | 0.38–1.40 | 1.30 | 0.9–1.7 |
Certolizumab pegol [176] | 0.67 | 0.21–1.13 | 0.98 | 0.34–1.63 |
Secukinumab [145, 177] | 0.5 | 0.11–0.89 | 1.2 | 0.29–2.11 |